Oscient Pharmaceuticals to Present at Roth Capital Partners New York Conference

Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Roth Capital Partners New York Conference on September 7, 2005 in New York. The Company’s President and CEO, Steven Rauscher, will provide an overview of the Company as well as an update on the market performance of FACTIVE(R) (gemifloxacin mesylate) tablets, the Company’s lead product. The presentation will begin at 2:00 PM ET on Wednesday and will be webcast through the Company’s website at www.oscient.com. An archive of the webcast will also be available for 90 days.

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. In addition to the oral tablet form, Oscient Pharmaceuticals is developing an investigational FACTIVE intravenous formulation for use in hospitalized patients. The Company is also promoting Auxilium Pharmaceuticals’ TESTIM(R) 1% testosterone gel to primary care physicians in the U.S. Oscient has a novel antibiotic candidate, Ramoplanin, in advanced clinical development for the treatment of Clostridium difficile-associated diarrhea (CDAD).